Viking Therapeutics (VKTX) Return on Capital Employed (2015 - 2026)
Viking Therapeutics (VKTX) reported Return on Capital Employed of 90.34% for Q1 2026, down 7049.0% on a YoY basis from 1.3% in Q1 2025, and down 49.5% sequentially from 60.43% in Q4 2025.
Viking Therapeutics (VKTX) Return on Capital Employed (2015 - 2026) Analysis & Trends
Viking Therapeutics (VKTX) has 12 years of Return on Capital Employed data on file, last reported at 90.34% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 7049.0% year-over-year to 90.34%; the trailing twelve-month figure through Mar 2026 stood at 90.34% (down 7049.0% YoY), and the FY2025 full-year result was 53.49%, down 2879.0% from the prior year.
- Return on Capital Employed fell to 90.34% in Q1 2026, from 60.43% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 13.38% in Q2 2024 to a low of 90.34% in Q1 2026.
- A 5-year average of 34.29% and a median of 30.12% in 2022 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed soared 3381 bps in 2024 and tumbled 7049 bps in 2026, its largest moves.
- Tracing VKTX's Return on Capital Employed over 5 years: stood at 48.3% in 2022, then surged by 41 bps to 28.29% in 2023, then jumped by 40 bps to 16.85% in 2024, then tumbled by 259 bps to 60.43% in 2025, then tumbled by 49 bps to 90.34% in 2026.
- Business Quant data shows VKTX's Return on Capital Employed at 90.34% in Q1 2026, 60.43% in Q4 2025, and 36.28% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Viking Therapeutics | 4.09 Bn | 4.09 Bn | - | -90.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -90.34% |
| Dec 31, 2025 | -60.43% |
| Sep 30, 2025 | -36.28% |
| Jun 30, 2025 | -26.10% |
| Mar 31, 2025 | -19.85% |
| Dec 31, 2024 | -16.85% |
| Sep 30, 2024 | -14.61% |
| Jun 30, 2024 | -13.38% |
| Mar 31, 2024 | -18.00% |
| Dec 31, 2023 | -28.29% |
| Sep 30, 2023 | -24.27% |
| Jun 30, 2023 | -30.79% |
| Mar 31, 2023 | -51.82% |
| Dec 31, 2022 | -48.30% |
| Sep 30, 2022 | -39.11% |
| Jun 30, 2022 | -34.48% |
| Mar 31, 2022 | -30.12% |
| Dec 31, 2021 | -26.67% |
| Sep 30, 2021 | -24.77% |
| Jun 30, 2021 | -22.01% |